aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
OliLux Biosciences was founded by Mireille Kamariza and Carolyn Bertozzi at Stanford University with a core mission to innovate tuberculosis (TB) detection and treatment management. The company’s primary product is DMN-Tre, a novel small molecule designed to provide rapid and low-cost TB detection alternatives. OliLux focuses on addressing the global health challenge of TB by offering efficient diagnostic solutions that can be deployed in resource-limited settings.
Notable affiliated individuals include Mireille Kamariza, the Founder and CEO, and Carolyn Bertozzi, a Founder and Scientific Advisor. OliLux has garnered attention for its groundbreaking work in TB diagnostics, leveraging advanced scientific research to create impactful healthcare solutions. The company’s achievements in developing DMN-Tre highlight its potential to significantly improve TB detection rates and treatment outcomes, contributing to global health advancements.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Diagnostics, Treatment
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Government
Geographic Exposure
Global
When was OliLux Biosciences founded?
OliLux Biosciences was founded in 2019.
Where is OliLux Biosciences’s headquarters located?
OliLux Biosciences’s headquarters is located in Wilmington, DE, US.
When was OliLux Biosciences’s last funding round?
OliLux Biosciences’s most recent funding round was for $400k (USD) in January 2021.
How many employees does OliLux Biosciences have?
OliLux Biosciences has 2 employees as of Feb 4, 2024.
How much has OliLux Biosciences raised to-date?
As of July 05, 2023, OliLux Biosciences has raised a total of $400k (USD) since Jan 1, 2021.
Add Comparison
Total Raised to Date
$400k
USD
Last Update Jan 1, 2021
Last Deal Details
$400k
USD
Jan 1, 2021
Grant
Total Employees Over Time
2
As of Feb 2024
OliLux Biosciences Address
251 Little Falls Drive
Wilmington,
Delaware
19808
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts